What makes Stayble unique

Stayble Therapeutics is dedicated to developing an effective treatment option for both degenerative disc disease (DDD) and lumbar disc herniation (LDH) using the company's drug candidate, STA363. This minimally invasive treatment offers an efficient and simple solution for the millions of individuals suffering from chronic back and leg pain, where pain medication or physical therapy have proven ineffective.

Read more

Get to know Stayble

Latest press releases

September 21, 2023

Stayble Therapeutics presents at Financial Stockholm’s investor meeting on September 25, 2023

Stayble Therapeutics AB ("Stayble" or "the Company") announces today that the Company will participate in the investor meeting "Investera som proffsen," organized by Financial Stockholm...

September 6, 2023

Stayble Therapeutics announces final patient´s last visit in the Phase 2b clinical study

Stayble Therapeutics AB ("Stayble" or the "Company") today announces that the Last Patient Last Visit (LPLV) in the Phase 2b clinical study in degenerative disc...

What makes stayble unique?

By using STA363 in two separate projects targeting DDD and LDH respectively, Stayble has advanced to a position at the forefront of injection-based, minimally invasive treatments for chronic back and leg pain. As Stayble has developed successfully, the Company is competing to become the market leader in second-line therapies for pain caused by degeneration and hernia.

About Stayble

One candidate- two treatments against chronic back and leg pain

About Stayble

Treatment of degenerative disc disease (DDD)

Stayble currently has one lead R&D project, which is a one-time injectionbased treatment (STA363) for patients suffering from degenerative disc disease and is currently being evaluated in an fully recruited ongoing clinical phase 2b trial.

DDD candidate

Treatment of lumbar disc herniation (LDH)

We recently seized the opportunity to launch the development of a second project, based on the same candidate (STA363), which aims to target patients suffering from unresolved herniated discs.

LDH Candidate

Invest in the future treatment of chronic back and leg pain

Stayble is listed on Nasdaq First North under the ticker STABL. You will find all relevant information on the Stayble share in our Investors section.


Bridging the therapeutic gap

The majority of patients suffering from degenerative disc disease and unresolved disc hernia are not helped by conservative treatment with analgesics and physiotherapy. With no long term treatment options than surgery most of these patient continues to suffer without improvment.

Stayble’s product STA363 will bridge the gap between conservative and radical therapy to the benefit of millions of patients presently left on their own to cope with sustained and disabling pain.

About Stayble